NCT02911116View on ClinicalTrials.gov

Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

March 5, 2020

Study Completion Date

May 28, 2020

Conditions
Uveitis
Interventions
DRUG

Ustekinumab

Subcutaneous Injection

DRUG

Ustekinumab

Intravenous Infusion

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT02911116 - Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) | Biotech Hunter | Biotech Hunter